Cti-1601, Nomlabofusp
Friedreich Ataxia
Phase II
Recruiting
An Open-Label Study of CTI-1601 in Subjects With Friedreich's Ataxia
Feb 15, 2024
―
Cti-1601
Friedreich Ataxia
Phase II
Completed
A Double-Blind, Placebo-Controlled, Dose Exploration Study of CTI-1601 in Adult Subjects With Friedreich's Ataxia
Oct 05, 2022
―
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Larimar Therapeutics, Inc. (ZA71) have in its pipeline
ZA71 is currently developing the following drugs: Nomlabofusp, Cti-1601, Nomlabofusp, Cti-1601, Nomlabofusp. These drug candidates are in various stages of clinical development as the company works toward FDA approval.